StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Sangamo Therapeutics's ebitda for the twelve months ending Mar 31, 2026 was -$119.90M. For fiscal 2025 it was -$117.28M. The highest annual figure on record is -$18.83M in fiscal 2009.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$117.28M–
FY2024Dec 31, 2024-$98.86M–
FY2023Dec 31, 2023-$258.94M–
FY2022Dec 31, 2022-$189.17M–
FY2021Dec 31, 2021-$173.90M–
FY2020Dec 31, 2020-$123.87M–
FY2019Dec 31, 2019-$101.25M–
FY2018Dec 31, 2018-$74.79M–
FY2017Dec 31, 2017-$54.86M–
FY2016Dec 31, 2016-$71.56M–
FY2015Dec 31, 2015-$45.87M–
FY2014Dec 31, 2014-$26.23M–
FY2013Dec 31, 2013-$26.14M–
FY2012Dec 31, 2012-$21.54M–
FY2011Dec 31, 2011-$35.18M–
FY2010Dec 31, 2010-$24.26M–
FY2009Dec 31, 2009-$18.83M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026-$31.23M–
Q4 FY2025Dec 31, 2025-$37.24M–
Q3 FY2025Sep 30, 2025-$34.56M-391.7%
Q2 FY2025Jun 30, 2025-$16.86M–
Q1 FY2025Mar 31, 2025-$28.61M–
Q4 FY2024Dec 31, 2024-$24.75M–
Q3 FY2024Sep 30, 2024$11.85M–
Q2 FY2024Jun 30, 2024-$35.84M–
Q1 FY2024Mar 31, 2024-$50.12M-332.9%
Q4 FY2023Dec 31, 2023-$60.23M–
Q3 FY2023Sep 30, 2023-$100.92M–
Q2 FY2023Jun 30, 2023-$119.32M–
Q1 FY2023Mar 31, 2023$21.52M–
Q4 FY2022Dec 31, 2022-$52.05M–
Q3 FY2022Sep 30, 2022-$51.85M–
Q2 FY2022Jun 30, 2022-$42.85M–
Q1 FY2022Mar 31, 2022-$42.43M–
Q4 FY2021Dec 31, 2021-$37.14M–
Q3 FY2021Sep 30, 2021-$45.88M–
Q2 FY2021Jun 30, 2021-$46.46M–
Q1 FY2021Mar 31, 2021-$44.43M–
Q4 FY2020Dec 31, 2020-$41.75M-1671.3%
Q3 FY2020Sep 30, 2020-$2.34M–
Q2 FY2020Jun 30, 2020-$36.57M–
Q1 FY2020Mar 31, 2020-$43.21M–
Q4 FY2019Dec 31, 2019$2.66M–
Q3 FY2019Sep 30, 2019-$28.09M–
Q2 FY2019Jun 30, 2019-$32.64M–
Q1 FY2019Mar 31, 2019-$43.18M–
Q4 FY2018Dec 31, 2018-$20.08M–
Q3 FY2018Sep 30, 2018-$15.78M–
Q2 FY2018Jun 30, 2018-$18.52M–
Q1 FY2018Mar 31, 2018-$20.41M–
Q4 FY2017Dec 31, 2017-$13.30M–
Q3 FY2017Sep 30, 2017-$12.62M–
Q2 FY2017Jun 30, 2017-$12.45M–
Q1 FY2017Mar 31, 2017-$16.49M–
Q4 FY2016Dec 31, 2016-$9.58M–
Q3 FY2016Sep 30, 2016-$18.95M–
Q2 FY2016Jun 30, 2016-$26.59M–

More Sangamo Therapeutics figures

See a number that looks wrong?